Medical therapy of clinically nonfunctioning (nonsecreting) low grade (grade 1–2) neuroendocrine neoplasms consists first-line first generation somatostatin analogs and second-line or third-line peptide receptor radiotherapy with radiolabeled beta-emitting analogs, Everolimus, Sunitinib, interferon-α. Second-generation like Pasireotide have no proven superiority over first-generation analogs. C...